ENG/中
老虎證券
市场
行情
24/7新闻
产品
Cash Boost账户
期权
A股通
港股
固定票息票据
美股
ETF
基金超市
美国国债
新加坡股
期货
Tiger BOSS Debit Card
老虎钱袋子
功能
经纪人
定投
CPF/SRS 投资
专栏
美股碎股
TigerAI
费用
综合账户
股票与ETF
期权、窝轮与牛熊证
期货
债券
基金超市
Cash Boost
股票与ETF
融资利率
活动
帮助
账户操作
如何开户
开户文件
账户类型
资金与转仓
入金
DDA快捷入金
出金
转入股票
转出股票
货币兑换
产品与交易
可交易产品
订单类型
交易规则
申报
融资融券
保证金与杠杆
风险管理
做空风险
基金超市
基金开户与交易
Cash Boost账户
Cash Boost 账户FAQ
如何开通 Cash Boost 账户
如何用Cash Boost 账户交易
如何绑定CDP证券账户
Tiger Boss Debit Card
常见问题
费用说明
如何充值
如何使用我的Debit card
账单报表
账单报表
股息(分红)
机构
Tiger Fund Management
机构服务
财富及资产管理人
自营交易机构
介绍经纪商
三方服务商
老虎API平台
登入
立即註冊
Toggle
美股
詳情
本頁面由Tiger Trade Technology Pte. Ltd.提供服務
2倍做多NVO ETF-Defiance
18.46
+0.1600
0.87%
成交量:
10.56萬
成交額:
194.00萬
市值:
5,165.29萬
市盈率:
- -
高:
18.57
開:
18.38
低:
18.25
收:
18.30
52周最高:
105.60
52周最低:
14.59
股本:
279.81萬
流通股本:
279.81萬
量比:
1.25
換手率:
3.77%
股息:
- -
股息率:
- -
淨資產收益率:
--
總資產收益率:
--
市淨率:
--
市盈率(LYR):
- -
資料載入中...
總覽
公司
新聞資訊
公告
概念
沒有相關數據
資金流向
資金流入:
資金流出:
實時
日
周
月
季度
年
新聞資訊
劍指全球市場!諾和諾德(NVO.US)擴建愛爾蘭工廠 欲藉口服版Wegovy搶佔市場份額
智通财经
·
4小時前
貝倫貝格:將諾和諾德目標價下調至360丹麥克朗
中金财经
·
8小時前
2026年,這22款藥物值得關注
药智网
·
11小時前
德銀:諾和諾德仍有機會重新把握肥胖症市場的機遇
环球市场播报
·
昨天
{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股,新股,港股,A股等全球金融理财产品。新加坡华人最信赖的在线投资平台,现在加入即享低费用,24/5 无时差炒美股投资理财!","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股,新股,港股,A股等全球金融理财产品。新加坡华人最信赖的在线投资平台,现在加入即享低费用,24/5 无时差炒美股投资理财!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/NVOX"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"NVOX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NVOX\",,,,,undefined,":{"symbol":"NVOX","market":"US","secType":"STK","nameCN":"2倍做多NVO ETF-Defiance","latestPrice":18.46,"timestamp":1770908469008,"preClose":18.3,"halted":0,"volume":105555,"delay":0,"changeRate":0.00874316939890711,"floatShares":2798101,"shares":2798101,"eps":0,"marketStatus":"交易中","change":0.16,"latestTime":"02-12 10:01:12 EST","open":18.38,"high":18.57,"low":18.25,"amount":1939994.7116699999,"amplitude":0.017486,"askPrice":18.51,"askSize":1020,"bidPrice":18.47,"bidSize":780,"shortable":3,"etf":2,"ttmEps":0,"tradingStatus":2,"nextMarketStatus":{"tag":"盤後交易","tradingStatus":3,"beginTime":1770930000000},"marketStatusCode":2,"adr":0,"exchange":"ARCA","adjPreClose":18.3,"sharesOutstanding":2798101,"nav":18.62,"aum":52100640.62,"bidAskSpread":0,"preHourTrading":{"tag":"盘前","latestPrice":18.46,"preClose":18.3,"latestTime":"09:27 EST","volume":8142,"amount":150488.691846,"timestamp":1770906469280,"change":0.16,"changeRate":0.008743,"amplitude":0.016421},"postHourTrading":{"tag":"盘后","latestPrice":18.35,"preClose":18.3,"latestTime":"19:57 EST","volume":9728,"amount":178409.5812,"timestamp":1770857876866,"change":0.05,"changeRate":0.002732,"amplitude":0.012749},"volumeRatio":1.245296,"impliedVol":0.8824,"impliedVolPercentile":0.568},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NVOX\",,,,,undefined,":{"symbol":"NVOX","floatShares":2798101,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":1.245296,"shares":2798101,"dividePrice":0,"high":18.57,"amplitude":0.017486,"preClose":18.3,"low":18.25,"week52Low":14.5902,"pbRate":"--","week52High":105.6,"institutionHeld":0,"latestPrice":18.46,"committee":-0.133333,"eps":0,"divideRate":0,"volume":105555,"delay":0,"ttmEps":0,"open":18.38,"prevYearClose":21.89,"prevWeekClose":17.59,"prevMonthClose":28.89,"prevQuarterClose":21.89,"fiveDayClose":14.7,"twentyDayClose":28.94,"sixtyDayClose":20.48},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NVOX\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-12-09","symbol":"NVOX","defaultRemindTime":1765290600000,"type":"split","dateTimestamp":1765256400000,"forFactor":8,"toFactor":1,"ratio":8}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NVOX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"NVOX\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"NVOX\",pageSize:4,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2610794788","title":"劍指全球市場!諾和諾德(NVO.US)擴建愛爾蘭工廠 欲藉口服版Wegovy搶佔市場份額","url":"https://stock-news.laohu8.com/highlight/detail?id=2610794788","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610794788?lang=zh_tw&edition=fundamental","pubTime":"2026-02-12 18:57","pubTimestamp":1770893858,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,诺和诺德计划加大在爱尔兰的投资,在当地生产其畅销减肥药Wegovy的口服版本,以供应美国以外的市场。诺和诺德首席执行官迈克·杜斯达尔表示,诺和诺德将扩建其位于爱尔兰中部阿斯隆的生产设施。杜斯达尔称,Wegovy口服药于1月初上市,成为有史以来最成功的药品首发之一,目前已有超过24万名美国患者服用。爱尔兰是全球制药制造中心之一。礼来在当地生产其重磅减肥和糖尿病药物的活性成分。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1404784.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"剑指全球市场!诺和诺德(NVO.US)扩建爱尔兰工厂 欲借口服版Wegovy抢占市场份额","news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["NVOX","LU0154236417.USD","NVOH","BK4007","IE00BKVL7J92.USD","LU1093756325.SGD","IE00BZ1G4Q59.USD","NVO","BK4532","BK4588","BK4585","BK4599","LU1093756168.USD"],"gpt_icon":0},{"id":"2610197339","title":"貝倫貝格:將諾和諾德目標價下調至360丹麥克朗","url":"https://stock-news.laohu8.com/highlight/detail?id=2610197339","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610197339?lang=zh_tw&edition=fundamental","pubTime":"2026-02-12 14:27","pubTimestamp":1770877621,"startTime":"0","endTime":"0","summary":"贝伦贝格将诺和诺德目标价从415丹麦克朗下调至360丹麦克朗。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260212/32014623.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK4585","BK4588","BK4007","NVOX","BK4599","LU0154236417.USD","NVO","IE00BZ1G4Q59.USD","LU1093756168.USD","IE00BKVL7J92.USD","NVOH","LU1093756325.SGD","BK4532"],"gpt_icon":0},{"id":"2610150992","title":"2026年,這22款藥物值得關注","url":"https://stock-news.laohu8.com/highlight/detail?id=2610150992","media":"药智网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610150992?lang=zh_tw&edition=fundamental","pubTime":"2026-02-12 11:27","pubTimestamp":1770866876,"startTime":"0","endTime":"0","summary":"目前,礼来已正式提交该药物的上市申请,有望在2026年实现获批。该药物的III期REDEFINE 4研究结果预计于2026年上半年揭晓。FDA预计将于2026年完成该药物的审评工作。2026年第一季度,预计辉瑞将公布MET-0971的IIb期临床试验数据。02肿瘤领域根据FirstWord Pharma,2026年,肿瘤领域有7款关键药物值得关注。吉利德计划于2026年在","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260212113614a6f1834d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260212113614a6f1834d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE00BKVL7J92.USD","LU0154236417.USD","BK4007","NVO","BK4532","BK4585","NVOX","IE00BZ1G4Q59.USD","NVOH","LU1093756168.USD","BK4588","LU1093756325.SGD","BK4599"],"gpt_icon":0},{"id":"2610935665","title":"德銀:諾和諾德仍有機會重新把握肥胖症市場的機遇","url":"https://stock-news.laohu8.com/highlight/detail?id=2610935665","media":"环球市场播报","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610935665?lang=zh_tw&edition=fundamental","pubTime":"2026-02-11 18:28","pubTimestamp":1770805680,"startTime":"0","endTime":"0","summary":"德意志银行分析师Emmanuel Papadakis写道,诺和诺德在适当的时候仍有机会重新把握其在肥胖症市场的机遇。该行仍对诺和诺德持乐观看法,该股市盈率已回落至十几倍的水平。 该公司Wegovy口服药的上市表现稳健,下半年有潜在的销量利好因素,而且或许最重要的是,关键的cagrisema数据仍有待公布。 该行将该股目标价从475丹麦克朗下调至400丹麦克朗,并维持买入评级。该股下跌2.4%,至307.55丹麦克朗。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-02-11/doc-inhmmvza3702737.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["IE00BZ1G4Q59.USD","LU1093756325.SGD","BK4588","NVOX","NVOH","BK4532","IE00BKVL7J92.USD","LU0154236417.USD","BK4599","NVO","BK4007","LU1093756168.USD","BK4585"],"gpt_icon":0}],"pageSize":4,"totalPage":18,"pageCount":1,"totalSize":72,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/NVOX\",params:#limit:6,delay:false,,,undefined,":[]}}